~~<i id='F6C40325D2'><strike id='F6C40325D2'><tt id='F6C40325D2'><pre id='F6C40325D2'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

focus

hotspot

author：explore 2025-09-30 00:36:48 - browse：49

Venture capitalist Alexis Borisy Vanessa Leroy for STAT

EQRx is done, sold for its cash.

The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Novavax promises a turnaround & Lilly roils the obesity market
Next article： Solving academic medical centers' existential crisis

focus

hotspot

leisure time

hotspot

AdobeWhenitcomestobringinganexperimentaldrugtomarketandsellingit,NovoNordisk,themakeroftheweightloss

WSS

Drastic changes should bring profitability, startup health insurers say

Arc Institute generative AI designs new CRISPR systems

FDA panel issues narrow recommendation for Covid vaccine booster doses

NVIDIA and Google execs on the future of AI and drug discovery

Readers respond to H5N1 and livestock movements, and more

What to know about Virgin Galactic's 1st mission taking paying customers to space

focus

hotspot

focus

Dobbs anniversary: the lost opportunity of abortion as health care

Readers respond to H5N1 and livestock movements, and more

Moonlake's readout produced a cash windfall. Risks remain

Wearables generate powerful data but its not useful to doctors, yet

Activists slam private health insurers over coverage restrictions

Can we make enough H5N1 bird flu vaccine if there's a pandemic?

Moonlake's readout produced a cash windfall. Risks remain

Glen Campbell's doctor discusses his public struggle with Alzheimer's

Moonlake's readout produced a cash windfall. Risks remain

South Korea throws huge K

hotspot

HIV vaccine remains elusive. Immunologists keep trying new ideas

Venture capitalist Bob Kocher on the state of digital health

Big Tobacco's 'harm reduction': Is it for real, or a sham?

It's time to retire 'poor historian' from clinicians' vocabularies

When prostate cancer spreads, where it goes matters

It's time to retire 'poor historian' from clinicians' vocabularies

hotspot

leisure time

hotspot

hotspot